{"schema_version":"secwatch.filing_event.v1","accession":"0000929638-24-001313","form_type":"8-K","ticker":null,"cik":"0001100397","company_name":"Ayala Pharmaceuticals, Inc.","filed_at":"2024-03-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.362493+00:00","generated_at":"2026-06-04T05:11:18.585864+00:00","sec_items":["2.01","3.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ayala sells AL102/AL101 to Immunome for $20M cash plus 2.18M shares; up to $37.5M milestones","bullets":["Closed sale of AL101 and AL102 programs to Immunome for $20M cash, 2,175,489 Immunome shares, and assumed liabilities.","Up to $37.5M in additional development/commercial milestone payments from Immunome.","March 1 Convertible Notes ($2M aggregate) converted into 6,666,666 shares of Ayala common stock upon closing.","Immunome (Nasdaq: IMNM) will advance AL102; Ayala (OTCQX: ADXS) retains potential milestone payments."],"urls":{"canonical":"https://secwatch.observer/filing/0000929638-24-001313","json":"https://secwatch.observer/filing/0000929638-24-001313.json","markdown":"https://secwatch.observer/filing/0000929638-24-001313.md","text":"https://secwatch.observer/filing/0000929638-24-001313.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1100397/000092963824001313/0000929638-24-001313-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1100397/000092963824001313/a8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T05:11:18.585864+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"52c7b01560b7b54df2666d86ea6fa0de2f6a323d","claim":"Ayala Pharmaceuticals, Inc. completed a disposition involving Immunome, Inc. for $20.0 million in cash plus 2,175,489 shares of common stock (closed 2024-03-25).","evidence_excerpt":"On March 25, 2024, the Company and Purchaser consummated the Asset Sale pursuant to the Asset Purchase Agreement, such that Purchaser (i) paid an upfront purchase price of $20.0 million in cash to the Company, less certain adjustments, (ii) issued the Company 2,175,489 shares of Immunome’s common stock","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1100397/000092963824001313/0000929638-24-001313-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"Immunome, Inc."},{"label":"Consideration","value":"$20.0 million in cash plus 2,175,489 shares of common stock"},{"label":"Closing","value":"2024-03-25"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}